Turning Point Brands, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TPB research report →
Range $90 – $115
Price Chart
About the company
Turning Point Brands, Inc. , along with its affiliated companies, is engaged in the creation, promotion, and distribution of a diverse array of branded consumer products. Its operations are structured into three distinct divisions: Zig-Zag Products, Stoker's Products, and NewGen Products.
- CEO
- David Glazek
- IPO
- 2016
- Employees
- 484
- HQ
- Louisville, KY, US
Get TickerSpark's AI analysis on TPB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $921.72M
- P/E
- 34.87
- Fwd P/E
- 40.66
- PEG
- -0.68
- P/S
- 1.83
- P/B
- 2.34
- EV/EBITDA
- 13.37
- Div Yield
- 0.64%
- Gross Margin
- 58.37%
- Op Margin
- 11.01%
- Net Margin
- 5.08%
- ROE
- 6.97%
- ROIC
- 6.97%
Latest fiscal year · YoY change
- Revenue
- $463.06M+28.4%
- Gross Profit
- $264.31M+31.1%
- Op Income
- $95.33M
- Net Income
- $58.16M+46.1%
- EPS
- $3.18+42.0%
- OCF Growth
- -14.4%
- FCF Growth
- -29.8%
- 52W High
- $146.90
- 52W Low
- $45.21
- 50D MA
- $61.61
- 200D MA
- $82.32
- Beta
- 0.97
- RSI (14)
- 24
- Avg Volume
- 422.37K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Turning Point Brands posted strong Q3 growth driven by Modern Oral, while continuing to invest heavily in distribution and infrastructure that are pressuring near-term EBITDA.· November 9, 2026
- Net sales rose 27.0% year over year to $151 million, with gross profit of $85 million and adjusted EBITDA of $18 million.
- Modern Oral was the clear growth engine: gross sales up 114% year over year and net sales up 103%, with the category now 49% of total revenue versus 31% a year ago.
- Management said FRE and ALP are still in early innings in brick-and-mortar, and the company is on track to increase chain store count by more than 70% in 2026.
- Gross margin was 56%, slightly down sequentially on a normalized basis, while SG&A was $75 million and down almost $2 million sequentially.
- The company reaffirmed full-year guidance for Modern Oral gross sales of $330 million to $350 million, net sales of $260 million to $270 million, and adjusted EBITDA of $70 million to $80 million.
Third-quarter net sales increased 27.0% year over year to $151 million. Gross profit was $85 million, up 21%, and gross margin was 56%, slightly down versus the second quarter on a normalized basis. Adjusted EBITDA was $18 million, down 41% year over year but up $3 million sequentially. Consolidated SG&A was $75 million, down almost $2 million sequentially. By segment, Stoker’s net sales increased 52.0% year over year to $114 million, driven by Modern Oral nicotine pouch net sales of $74 million, up 103%, and Modern Oral gross revenue of $94 million, up 114%. Zig-Zag net sales were down 15% year over year to $37 million. Management reiterated full-year Modern Oral gross sales guidance of $330 million to $350 million, Modern Oral net sales guidance of $260 million to $270 million, and adjusted EBITDA guidance of $70 million to $80 million. The company also expects an effective tax rate of 23% to 26% going forward, fourth-quarter CapEx of $1 million to $2 million excluding Modern Oral projects, and about $3.5 million of PMTA-related spending in the fourth quarter.
David Glazek framed the quarter as evidence that the company’s strategy is working: use cash flow from heritage brands to build a leading position in Modern Oral. He emphasized that consumer adoption remains strong, chain distribution is expanding, and FRE and ALP are still early in their rollout, with more than 70% chain store count growth targeted in 2026. His tone was upbeat and confident, repeatedly describing the opportunity as large and long-term, while noting U.S. manufacturing is expected to begin in 2027 but remains dependent on FDA timing.
Andrew Flynn focused on the financial tradeoffs of scaling the business. He highlighted $151 million of net sales, $85 million of gross profit, 56% gross margin, $75 million of SG&A, and $18 million of adjusted EBITDA, noting that profitability was intentionally pressured by sales and marketing investment. He said free cash flow was $3.5 million, cash ended at $251 million, and the company repurchased $10.0 million of stock in the quarter while keeping capital allocation measured. He also reaffirmed the full-year outlook and noted fourth-quarter PMTA spending of roughly $3.5 million, with another $1 million to $2 million of CapEx excluding Modern Oral projects.
Analysts focused on why fourth-quarter Modern Oral guidance looks conservative relative to the growth seen earlier in the year. Management said there was no change in the underlying trajectory, but timing issues near year-end and holiday-related shipment shifts can move revenue between quarters, and the company does not have much additional visibility since updating guidance on September 21. Questions also centered on distribution timing, with management saying FRE is ahead of ALP in brick-and-mortar and chain negotiations, while ALP is earlier but progressing well in independents and beginning to engage larger chains. On PMTA and manufacturing, management said Louisville-related submissions are complete and that a second PMTA path is being prepared to keep the current application on track while listing U.S. manufacturing separately.
The bull case from the call is that Modern Oral is scaling quickly and still appears early in its distribution cycle. Management pointed to strong consumer adoption, expanding chain placements, improving velocity where more SKUs are available, and a category that they believe is maturing in a way that will favor the strongest brands. They also maintained full-year guidance and sounded confident that the current investment phase can support much larger long-term revenue and profit.
The main risks are near-term margin pressure and execution timing. Management acknowledged that heavy spending on sales, marketing, merchandising, and PMTA work is keeping EBITDA well below what the business could eventually generate, while revenue can swing from quarter to quarter based on chain rollout timing and holiday loading. They also noted dependence on FDA timing for U.S. manufacturing and that Zig-Zag is stable but opaque because a meaningful portion of volume sits in non-measured channels.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 93.7%
- Shares Outstanding
- 19.88M
- Float Shares
- 18.63M
of shares held by institutions
248 13F filers
Buy/sell ratio 8.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 1.54M | ▼ 80.98K |
| Vanguard Group Inc | 1.45M | ▲ 61.31K |
| Divisadero Street Capital Management, LP | 1.27M | ▲ 969.73K |
| Thrivent Financial For Lutherans | 1.20M | ▼ 36.69K |
| First Trust Advisors LP | 1.05M | ▲ 77.31K |
| Vanguard Capital Management LLC | 823.79K | ▲ 1.29K |
| American Century Companies Inc | 774.26K | ▲ 146.80K |
| Copeland Capital Management, LLC | 708.51K | ▲ 18.18K |
| Maple Rock Capital Partners Inc. | 686.80K | ▲ 250.80K |
| T. Rowe Price Investment Management, Inc. | 588.63K | ▲ 219.58K |
| Two Sigma Investments, LP | 568.20K | ▲ 53.24K |
| Bank Of America Corp | 557.46K | ▲ 266.64K |
Held by 217 ETFs
Biggest fund positions in TPB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | Reddy Rohith | other | 1,295 |
| May 12, 26 | Wigginton Brian | sell | 4,000 |
| May 11, 26 | Wexler Lawrence | other | 1,295 |
| May 11, 26 | Shanahan Kathleen M | other | 1,295 |
| May 11, 26 | Usher Stephen | other | 1,295 |
| May 11, 26 | Diao H.C. Charles | other | 1,295 |
| May 11, 26 | Frushone Ashley Davis | other | 1,295 |
| May 11, 26 | Catsimatidis John A. Jr | other | 1,295 |
| May 11, 26 | Baxter Gregory H.A. | other | 1,295 |
| Mar 24, 26 | Purdy Graham | other | 8,638 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TPB coverage
Recent articles, reports, and earnings notes.
No research on TPB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TPB report →Why Turning Point Brands Stock Got Socked Today
fool.com · Nov 16
What Turning Point Brands (TPB) Said on Its Q3 Earnings Call
marketbeat.com · Nov 9
Turning Point Brands, Inc. (TPB) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
ALP Makes Its Mark on New York City with first ever Nicotine Pouch Brand Flagship Pop-Up in the Country
prnewswire.com · Nov 9
Turning Point Brands (TPB) Tops Q3 Earnings and Revenue Estimates
zacks.com · Nov 9
Turning Point Brands Announces Third Quarter 2026 Results
businesswire.com · Nov 9
Turning Point Brands Declares Common Stock Dividend
businesswire.com · Nov 2
Turning Point Brands to Host Q3 2026 Conference Call
businesswire.com · Oct 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.